Results 131 to 140 of about 20,877 (256)

Fixed Drug Eruptions in Malagasy Children: Clinical Observations and Characteristics. [PDF]

Case Rep Dermatol Med
Rakotonandrasana F, Sendrasoa FA, Raharolahy O, Desana S, Ralimalala VN, Razafimaharo TI, Sata M, Andrianarison M, Ramarozatovo LS, Rabenja FR, Ranaivo IM.   +10 more
europepmc   +1 more source

Dermatologic Toxicities Associated With Novel Pan‐RAS/RAF Inhibitors

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Background The mitogen‐activated protein kinase (MAPK) pathway plays a key role in cell‐cycle regulation and tumor progression in cancer. Dermatologic toxicities (DTs) to newer pan‐RAS (RMC‐6236) and pan‐RAF (LXH254/naporafenib) inhibitors are emerging.
Lin J. He, Shaymaa Hegazy, Phyu P. Aung, Priyadharsini Nagarajan, Fiorinda Muhaj, Adrienne N. Choksi, Ana M. Ciurea, Kelly C. Nelson, Doina Ivan, Carlos A. Torres‐ Cabala, Victor G. Prieto, Jonathan L. Curry   +11 more
wiley   +1 more source

Generalized fixed drug eruptions in skin of color. [PDF]

Int J Womens Dermatol
Grewal A, Pei S, Kuraitis D.
europepmc   +1 more source

Treatments for Molluscum contagiosum: A systematic review

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Molluscum contagiosum (MC) is a viral skin infection that poses significant physical and psychosocial burdens, particularly in pediatric and immunocompromised populations. Despite the availability of various treatment options, comparative efficacy and safety data remain limited.
Ou Jia (Emilie) Wang, Mahek Shergill, Ammar Saed Aldien, Ilya Mukovozov   +3 more
wiley   +1 more source

Morbilliform Eruptions: Differentiating Low-Risk Drug Eruptions, Severe Cutaneous Adverse Reactions, Viral Eruptions, and Acute Graft-Versus-Host Disease. [PDF]

Am J Clin Dermatol
Yan A, Madigan L, Korman A, Shearer S, Dulmage B, Patel T, Milani-Nejad N, Chung C, Fisher K, Kaffenberger B.   +9 more
europepmc   +1 more source

Drug Eruptions

International Journal of Clinical Practice, 1968
openaire   +2 more sources

S1 Guideline: Therapy of generalized pustular psoriasis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The S1 guideline “Therapy of generalized pustular psoriasis (GPP)” is a German guideline developed in accordance with the criteria of the AWMF. The full version addresses clinical presentation, pathogenesis, diagnosis and differential diagnosis, comorbidities, and therapy.
Rotraut Mößner, Neda Cramer, Sascha Gerdes, Ulrike Hüffmeier, Andreas Körber, Kai Krause, Christian Kromer, Katharina Antonia Langen, Sandra Philipp, Knut Schäkel, Michael P. Schön, Michael Schultheis, Lukas Sollfrank, Petra Staubach, Michael Sticherling, Johannes Wohlrab, Dagmar Wilsmann‐Theis, Cornelia Paul   +17 more
wiley   +1 more source

Copaiba Balsam‐Induced Contact Dermatitis Mimicking Wells' Cellulitis in a Child

Contact Dermatitis, EarlyView.
Nathalia Bellon, Angéline Girault, Morgane Seyler, Annonciade Frassati‐Biaggi, Anne Welfringer, Christine Bodemer   +5 more
wiley   +1 more source

The different face of skin‐rash induced by brentuximab vedotin

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background: Brentuximab vedotin (BV) is a targeted therapy for CD30‐expressing lymphomas, including Hodgkin lymphoma (HL) and cutaneous T‐cell lymphoma (CTCL). While peripheral neuropathy is the most common adverse event, BV‐induced skin rashes are less frequent and not well characterized.
Alessandro Pileri, Tullio Brunetti, Serena Rupoli, Gianluca Cafasso, Corrado Zengarini, Staphano Cedirian, Federico Bardazzi, Cosimo Misciali, Michela Starace, Claudio Agostinelli, Gaia Goteri, Erika Morsia   +11 more
wiley   +1 more source

Clinical Efficacy of CBCT and 3D‐Printed Replicas in Molar Autotransplantation: A Controlled Clinical Trial

Dental Traumatology, Volume 41, Issue 2, Page 161-170, April 2025.
ABSTRACT Background/Aim To evaluate the efficacy of the combined cone‐beam (CBCT)/3D‐replicas protocol on the clinical and radiographic outcomes of autotransplanted molars. Material and Methods Controlled clinical trial registered ISRCTN13563091 from August 2019 to September 2022.
Miks Lejnieks, Ilze Akota, Gundega Jākobsone, Laura Neimane, Sergio E. Uribe   +4 more
wiley   +1 more source